Loading...
•
Mar 31
Enanta Pharmaceuticals Q2 2025 Earnings Report
reported financial results for its fiscal second quarter ended March 31, 2025
Key Takeaways
Enanta Pharmaceuticals reported a net loss of $22.6 million, or $1.06 per diluted common share, for the fiscal second quarter ended March 31, 2025. Total revenue was $14.9 million, primarily from royalty revenue. The company ended the quarter with $193.4 million in cash and marketable securities, further strengthened by a $33.8 million tax refund received in April 2025.
Total revenue for the quarter was $14.9 million, a decrease from $17.1 million in the prior year period.
Net loss for the quarter was $22.6 million, an improvement from a net loss of $31.2 million in the same period last year.
Research and development expenses decreased to $28.1 million from $35.6 million in the prior year quarter.
Cash, cash equivalents, and short-term marketable securities totaled $193.4 million as of March 31, 2025.
Enanta Pharmaceuticals
Enanta Pharmaceuticals
Enanta Pharmaceuticals Revenue by Segment
Revenue by Segment
Royalty Revenue
CapyFin.com Forward Guidance
Enanta expects its current cash, cash equivalents, and marketable securities, along with future royalty revenue and a received tax refund, to fund operations into fiscal 2028. The company anticipates reporting topline data from its RSVHR study in late Q3 2025 and selecting a STAT6 development candidate in the second half of 2025.
Positive Outlook
- Sufficient cash position expected to fund operations into fiscal 2028.
- Met target enrollment for the Phase 2 RSVHR study of zelicapavir.
- On track to report topline data for the RSVHR study in late Q3 2025.
- Progressing with the STAT6 program and plans to select a development candidate in 2H 2025.
- IND enabling studies for the KIT inhibitor EPS-1421 are ongoing.
Challenges Ahead
- Revenue decreased compared to the prior year period.
- Ongoing net losses.
- Interest and investment income decreased year-over-year.
- Subject to a royalty sale transaction affecting a portion of future royalty revenue until June 30, 2032.
- Legal expenses related to the patent infringement lawsuit against Pfizer are a factor in G&A expenses.